Mounjaro Vial

Mounjaro (tripeptide) in vial form is used for subcutaneous injection to manage type 2 diabetes and support weight loss. It offers flexibility in dosing and is suitable for patients who prefer vial-based injections.
Benefits:
Effective blood sugar control
Significant weight reduction potential
Long-acting, weekly dosing
Can support metabolic health
Dosage:
Start at 2.5 mg once weekly
Titrate up to 15 mg/week based on response
Administer via subcutaneous injection
Warnings and Precautions:
May cause GI upset during initial dose increases
Contraindicated in patients with a personal or family history of MTC
Monitor for signs of pancreatitis
Usage Instructions:
Prepare injection using a sterile technique
Use only as directed by a healthcare provider
Rotate injection sites to prevent irritation
Storage Information:
Keep refrigerated (2–8°C)
Do not freeze
Use within 28 days once opened
Common Side Effects:
Indigestion
Diarrhea
Fatigue
Decreased appetite
More information about Mounjaro:
Product Monograph – Health Canada
U.S. Food and Drug Administration Medication Guide